Gitnux/Report 2026

Clean Room Pharmaceutical Industry Statistics

238Statistics
81Sources
12Sections
1Visuals
44mRead
Clean Room Pharmaceutical Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The clean room pharmaceutical industry at a glance

The global pharmaceutical cleanroom technology market was valued at $7.05 billion in 2025 and is projected to grow rapidly as sterile drugs, biologics and advanced therapies expand.

$7.05B[61]
Global market size, 2025
12.30%[61]
Forecast CAGR, 2026–2033
45%[62]
Pharmaceutical category share, 2025
38%[34]
Top-five supplier share, 2025
Market size
The global pharmaceutical cleanroom technology market was valued at $7.05 billion in 2025. The market includes cleanroom equipment, consumables and services used by pharmaceutical and biotechnology manufacturers.[61]
Forecast & CAGR
The market is forecast to reach $19.10 billion by 2033, representing a 12.30% CAGR from 2026 to 2033. Growth is linked to rising demand for sterile drug manufacturing and contamination-control infrastructure.[61]
Market share & regions
North America accounted for 40% of the global cleanroom technology market in 2025, while Asia-Pacific was identified as the fastest-growing region, with an estimated 7.2% CAGR through 2032. Pharmaceutical cleanroom demand is also expanding in Europe as manufacturers upgrade facilities for revised sterile-manufacturing requirements.[62][34]
Segmentation
The market is segmented by product into equipment, consumables and services, and by cleanroom type into standard and modular facilities. End users include pharmaceutical companies and biotechnology companies; broader cleanroom technology classifications also include HVAC systems, HEPA filters, fan-filter units, apparel, wipes and disinfection products.[61][63]
Key players & concentration
Major suppliers include Illinois Tool Works, Exyte, DuPont, Ansell and Azbil Telstar. The five leading companies together held approximately 38% of the global cleanroom technology market in 2025, while Illinois Tool Works held more than 5%.[34]
Pricing
High-specification ISO 5 pharmaceutical and biotechnology facilities were estimated to cost approximately $400–$600 or more per square foot in 2025, including filtration and HVAC. Costs vary substantially with room classification, containment, validation, automation and facility size.[47]
Trends, drivers & challenges
Demand is being driven by biologics, mRNA vaccines, advanced therapies and increased sterile fill-finish capacity. Key challenges include energy-intensive HVAC systems, validation costs, microbial and particulate control, skilled-labor requirements and the need to maintain compliance during construction or retrofit work.[62][64]
Consumer behavior & competition
Pharmaceutical manufacturers increasingly favor modular and flexible cleanroom solutions that shorten deployment timelines and support changing production volumes. Competition is based on contamination-control performance, regulatory validation, lifecycle cost, delivery speed and integrated services rather than equipment price alone.[61][15]
M&A
M&A activity remained active in 2026: G-CON Manufacturing acquired Atmos-Tech Industries on March 23, 2026, expanding its cleanroom systems, components and services portfolio. Cleanova also announced acquisitions of Airflotek and TES-Clean Air Systems in January 2026, adding filtration and controlled-environment capabilities serving pharmaceutical and biotechnology production.[65][66]
Regulation
FDA guidance identifies ISO 5 as the critical environment for exposed sterile drug products during aseptic processing, with a limit of 3,520 particles of at least 0.5 micrometres per cubic metre. EU GMP Annex 1 sets the same 3,520-particle limit for Grade A areas at rest and in operation and requires classification in both states.[64][67]
Latest news
In April 2026, QleanAir announced two U.S. cleanroom agreements worth approximately $1.51 million in total for USP 797/800-compliant pharmacy-compounding environments. In September 2026, Moqlero reported that a major pharmaceutical group had selected its platform for cleanroom qualification and monitoring at a new multibillion-dollar U.S. production site targeted for completion in 2029.[18][68]

02 Ranking

Top 9 Companies in the Clean Room Pharmaceutical Industry

The leading companies in the clean room pharmaceutical industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 11, 2026 · Next review December 11, 2026

Verdict

Ecolab leads Gitnux's 2026 clean room pharmaceutical ranking with an Overall score of 9.1, with offers cGMP cleaners, disinfectants and contamination-control programs for pharmaceutical plants. G-CON is the highest-ranked prefabricated cleanroom manufacturer at 8.9, with prefabricated POD cleanrooms for pharmaceutical, biotech and advanced-therapy production.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in cleanroom disinfection

    Ecolab

    US

    Ranked #1 · 9.1 · Cleanroom disinfection

    Why we picked it: Its cleanroom chemistry and contamination-control programs target pharmaceutical plant cGMP environments.

    See in ranking ↓Visit ecolab.com ↗

  2. Leader in prefabricated cleanrooms

    G-CON

    US

    Ranked #2 · 8.9 · Prefabricated cleanrooms

    Why we picked it: Its prefabricated POD cleanrooms cover pharmaceutical and biotech production environments.

    See in ranking ↓Visit gconbio.com ↗

  3. Leader in cleanroom components

    Purever

    PT

    Ranked #3 · 8.7 · Cleanroom components

    Why we picked it: Its cleanroom panels, doors and technical environments support life-science facilities worldwide.

    See in ranking ↓Visit purever.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 9 companies in the clean room pharmaceutical industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Ecolab

Cleanroom disinfection · US

9.1
2

G-CON

Prefabricated cleanrooms · US

8.9
3

Purever

Cleanroom components · PT

8.7
4

Illinois Tool Works

Cleanroom consumables · US

8.7
5

Labconco

Sterile compounding equipment · US

8.2
6

DuPont

Cleanroom garments and protective materials · US

8.2
7

Terra Universal

Modular cleanrooms and contamination-control equipment · US

8.1
8

Angstrom Technology

Modular pharmaceutical cleanroom design and manufacture · US

8.0
9

COLANDIS

Cleanroom technology and contamination-control equipment · DE

7.6

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 11, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 11). Top 9 companies in the clean room pharmaceutical industry. In Clean Room Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/clean-room-pharmaceutical-industry-statistics/#top-companies

report visual · Comparison

Global cleanroom facility market size

Global cleanroom facility market size: $50.2B in 2019, $50.2B in 2019.

2024 (forecast)$70.0B
2023 (forecast)$65.7B
2022 (forecast)$62.0B
2021 (forecast)$57.6B
2020 (forecast)$50.4B
2019$50.2B
source-verifiedwww1.hkexnews.hk2024

04 Statistics

Technology & Innovation

AI and automation adoption figures concentrate on validation monitoring, optimization and digital twins in 2025. The data also ties equipment build-outs to aseptic facility investment, including $160 million for a 2026 start.

AI in the clean room pharmaceutical industry

  • 16% of pharmaceutical and biotechnology organizations had implemented AI for real-time validation monitoring in clinical manufacturing in 2025.[1]
  • 18% of pharmaceutical and biotechnology organizations had implemented AI for real-time process optimization in clinical manufacturing in 2025.[1]
  • 19% of pharmaceutical and biotechnology organizations had implemented AI-driven digital twins for process replication in clinical manufacturing in 2025.[1]
  • 7.6% of pharmaceutical companies used AI to optimize production processes in 2024.[2]
  • 26% of EU pharmaceutical companies reported using at least one AI technology in manufacturing in 2024.[2]
  • 21% of pharmaceutical and biotechnology organizations had implemented AI for multivariate analysis in clinical manufacturing in 2025.[1]

Automation in the clean room pharmaceutical industry

  • More than 75% of pharmaceutical organizations reported using some form of advanced automation in 2024.[3]
  • 8% of pharmaceutical organizations had applied advanced automation capabilities across all or most processes in 2024.[3]
  • 60% of pharmaceutical companies planned to explore or increase use of advanced technologies during the 18 months following the 2024 survey.[3]
  • Robotic process automation was classified among the more advanced or well-adopted Pharma 4.0 technologies in the 2023 ISPE survey.[4]

Digital Transformation in the chemicals and materials sector (sector benchmark)

  • Among ASUG chemicals-industry members, 46% ranked automation among their leading technology focus areas in 2025.[5]
  • Across European chemical subindustries, 65% of companies viewed digitalization as an opportunity that would significantly impact their activities in 2024.[6]
  • Among EII businesses, 68% reported adopting AI in 2024, with an estimated 10% productivity increase.[6]
  • Among ASUG chemicals-industry members, 57% identified moving to SAP S/4HANA as a top focus area in 2025.[5]

Technology Adoption in the chemicals and materials sector (sector benchmark)

  • Among chemicals organizations surveyed by IBM, 49% had implemented AI for quality inspection or defect detection in 2025.[7]
  • Among chemicals organizations surveyed by IBM, 49% had implemented AI for production planning and scheduling in 2025.[7]
  • Among chemicals organizations surveyed by IBM, 53% had implemented AI for real-time process control and optimization in 2025.[7]
  • Among chemicals organizations surveyed by IBM, 45% had implemented AI for supply-chain optimization in 2025.[7]

Cloud Computing in the chemicals and materials sector (sector benchmark)

  • Among EII businesses, 2% reported decreased productivity from cloud computing in 2024.[6]
  • Across chemical-sector companies surveyed by Arthur D. Little and Cefic, 15% planned to migrate to cloud computing in coming years in 2023.[8]
  • Across chemical-sector companies surveyed by Arthur D. Little and Cefic, more than 35% had at least partially migrated to cloud computing in 2023.[8]
  • Among EII businesses, 52% reported increased productivity from cloud computing in 2024, while 46% reported no change.[6]

Big Data in the chemicals and materials sector (sector benchmark)

  • Among EII businesses, 48% reported increased productivity from big data in 2024.[6]
  • Among EII businesses, 6% reported decreased productivity from big data in 2024.[6]
  • Among ASUG chemicals-industry members, 49% cited gaining actionable insights from data and analytics as a current challenge in 2025.[5]
  • Among EII businesses, 44% reported no productivity change from big data in 2024.[6]

IoT in the chemicals and materials sector (sector benchmark)

  • Across European countries, 29% of firms used IoT on average in 2021.[9]
  • Among EII businesses, 56% reported no productivity change from IoT in 2024.[6]
  • Across 23 European countries, close to one-third of manufacturing firms used IoT in 2021.[9]
  • Among EII businesses, 44% reported increased productivity from IoT in 2024.[6]

05 Statistics

Data & Analytics

Teams shift from spreadsheets to integrated electronic data management, with 55% reporting a data-and-analytics center of excellence in 2023. In 2026, 89% said data use improved decision-making processes.

Business intelligence in the clean room pharmaceutical industry

  • 55% of pharmaceutical manufacturers established a data-and-analytics center of excellence, according to an industry survey, 2023.[10]
  • 68% of pharmaceutical companies planned to use advanced analytics, according to an industry survey, 2023.[10]
  • 99% of pharmaceutical executives reported that their teams used spreadsheets for revenue management, according to an industry survey, 2023.[10]
  • 64% of pharmaceutical executives purchased benchmarking data to support decision-making, according to an industry survey, 2023.[10]
  • 96% of pharmaceutical companies used external data sources for revenue-management insight, according to an industry survey, 2023.[10]
  • 45% of pharmaceutical executives reported using data in all revenue-management decisions, according to an industry survey, 2023.[10]

Data analytics in the clean room pharmaceutical industry

  • 68% of surveyed pharmaceutical companies used continued-process-verification information beyond GMP compliance, Spain and Portugal, 2022.[4]
  • 25% of surveyed pharmaceutical companies had estimated the cost of digitizing or automating continued process verification, Spain and Portugal, 2022.[4]
  • 46% of surveyed pharmaceutical companies had medium-to-advanced digital data management with integrated electronic data solutions, Spain and Portugal, 2022.[4]
  • 11% of surveyed pharmaceutical companies used advanced analytics for continued process verification, Spain and Portugal, 2022.[4]
  • 82% of surveyed pharmaceutical companies included critical quality, process and material attributes in continued-process-verification monitoring, Spain and Portugal, 2022.[4]
  • 71% of surveyed pharmaceutical companies reported having personnel trained in statistics or data science, Spain and Portugal, 2022.[4]

Data Quality in the chemicals and materials sector (sector benchmark)

  • 89% of manufacturers said data use improved their decision-making processes in 2026, across the surveyed manufacturing sector.[11]
  • 42% of manufacturers had a process to verify manufacturing-data accuracy and quality in 2026, while 51% did not.[11]
  • 80% of manufacturers reported a measured value for their operational data in 2026, across the surveyed manufacturing sector.[11]
  • 44% of companies in the manufacturing survey reported AI-project failures caused by poor data quality in 2025, across surveyed manufacturers.[12]
  • 67% of supply-management organizations said their data quality was better or significantly better than two years earlier in 2024.[13]
  • 49% of supply-management organizations rated their data quality as good or excellent in 2024, based on an Institute for Supply Management survey.[13]

Data Governance in the chemicals and materials sector (sector benchmark)

  • 90% of supply-management organizations agreed or strongly agreed that data governance was necessary in 2024.[13]
  • 28% of manufacturers had a data-governance leader in 2026, across the Manufacturing Leadership Council survey.[11]
  • 61% of supply-management organizations had a dedicated data-governance function in 2024, based on a survey of more than 121 respondents.[13]
  • 67% of GCC chemical companies had established performance management or KPIs around digital supply chains in 2022.[14]
  • 52% of global chemical companies had established performance management or KPIs around digital supply chains in 2022.[14]
  • 46% of GCC chemical companies had established common data standards with collaboration partners in 2022.[14]

KPIs in the clean room pharmaceutical industry

  • 18% of surveyed pharmaceutical companies tracked only critical quality attributes in continued process verification, Spain and Portugal, 2022.[4]
  • 71% of surveyed pharmaceutical companies reported employing statisticians or data scientists for process-monitoring work, Spain and Portugal, 2022.[4]
  • 68% of surveyed pharmaceutical companies used continued-process-verification results for purposes beyond GMP compliance, including process improvement and KPI use, Spain and Portugal, 2022.[4]
  • 25% of surveyed pharmaceutical companies had performed cost estimates for continued-process-verification digitization or automation, Spain and Portugal, 2022.[4]
  • 32% of surveyed pharmaceutical companies used continued-process-verification information only for GMP compliance, Spain and Portugal, 2022.[4]
  • 46% of surveyed pharmaceutical companies had medium-to-advanced integrated electronic data management for process verification, Spain and Portugal, 2022.[4]

06 Statistics

Strategy & Growth

Capacity and site build-outs drive cleanroom demand, with examples like $771 million for Novartis advanced manufacturing infrastructure in North Carolina. Regulatory and classification milestones also show up via ISO 8 and ISO classes 8 and 9.

Growth in the clean room pharmaceutical industry

  • $23 billion was Novartis’s planned five-year United States infrastructure investment announced with its North Carolina manufacturing hub.[15]
  • 10.7% was Fagron’s 2024 revenue growth, bringing revenue to €315.4 million across its pharmaceutical services and products.[16]
  • €166 million was Gerresheimer’s investment in expanding United States production of pharmaceutical inhaler and auto-injector systems.[15]
  • 17% was Syntegon Pharma’s 2024 increase in order intake, according to the company’s report on its pharmaceutical and biotech business.[17]
  • 11% was Syntegon Pharma’s 2024 revenue growth, while group revenue reached €1.6 billion.[17]
  • $771 million was Novartis’s announced investment in Durham and Morrisville, North Carolina, for advanced pharmaceutical manufacturing infrastructure.[15]

Differentiation in the clean room pharmaceutical industry

  • USP <797> was identified by QleanAir as a United States demand driver for hospital-pharmacy and drug-preparation cleanrooms.[18]
  • ISO 8 cleanroom capacity at ChemCon was designed with a novel air-pressure cascade preventing air from escaping the controlled environment.[19]
  • ISO 8 was the classification of ChemCon’s new cleanroom, which was approved for GMP production of pharmaceutical active ingredients in 2024.[19]
  • ISO Classes 8 and 9 will define approximately 130,000 square feet of Gerresheimer’s expanded pharmaceutical production cleanrooms in Georgia.[15]
  • GMP approval was obtained for ChemCon’s new pharmaceutical ISO 8 cleanroom facility in Freiburg in 2024.[19]

Mergers and acquisitions in the clean room pharmaceutical industry

  • $16.5 billion was the announced value of Novo Holdings’ 2024 acquisition of Catalent, a global pharmaceutical development and manufacturing services company.[20]
  • $2.9 billion was Novartis’s announced 2024 acquisition price for Morphosys AG.[21]
  • Four major pharmaceutical manufacturing M&A deals in the first half of 2023 ranged from $125 million to $4.3 billion.[22]
  • $1.3 billion was Merck & Co.’s announced 2024 acquisition value for EyeBio, including contingent consideration.[21]
  • October 18, 2022 was the acquisition date of Germfree Laboratories by EW Healthcare Partners, expanding ownership of modular cleanroom manufacturing capabilities.[23]
  • $2.2 billion was Sanofi’s 2024 purchase price for Inhibrx’s INBRX-101 asset, one of the year’s targeted pharmaceutical acquisitions.[21]

Strategic partnerships in the clean room pharmaceutical industry

  • Plant 5 at Franz Ziel was being developed in 2024 to support pharmaceutical cleanroom technology distribution worldwide through its Körber Pharma partnership.[15]
  • $2.2 billion was the potential value of Takeda’s 2024 strategic partnership with Degron Therapeutics.[21]
  • $2.4 billion was the announced value of Ono Pharmaceutical’s 2024 strategic transaction with Deciphera Pharmaceuticals.[21]
  • $2.0 billion was the potential value of Boehringer Ingelheim’s 2024 strategic partnership with Ribo.[21]
  • $2.2 billion was the potential value of Takeda’s 2024 strategic partnership with Kumquat Biosciences.[21]
  • $2.066 billion was the potential value of Roche’s 2024 strategic partnership with Moma Therapeutics.[21]

07 Statistics

People & Workforce

Workforce posting levels vary across 2021–2024, while 2026 training needs are quantified for Ireland. Remote and hybrid shares are also tracked, including 61% hybrid preference among U.S. remote-capable employees.

Hiring in the clean room pharmaceutical industry

  • 284,466 pharmaceutical industry job postings were recorded in the United States in 2022.[24]
  • 211,020 pharmaceutical industry job postings were recorded in the United States in 2021.[24]
  • 215,539 pharmaceutical industry job postings were recorded in the United States in 2024.[24]
  • Merck & Co. was among the leading pharmaceutical hiring companies by unique job postings in the United States during 2021–2024.[24]
  • Pfizer was among the leading pharmaceutical hiring companies by unique job postings in the United States during 2021–2024.[24]

Employee retention in the clean room pharmaceutical industry

  • 8.5% was Merck’s overall global employee turnover rate in 2020.[25]
  • 11.1% was Merck’s overall global employee turnover rate in 2021.[25]
  • 4.5% was Merck’s manufacturing-division voluntary turnover rate in 2024.[25]
  • 6.9% was Merck’s overall global employee turnover rate in 2024.[25]
  • 4.6% was Merck’s voluntary global employee turnover rate in 2024.[25]

Remote Work in the chemicals and materials sector (sector benchmark)

  • Across U.S. remote-capable employees, 25% worked exclusively remotely in August 2026.[26]
  • Among U.S. energy, natural-resources and chemicals workers, 8% preferred fully remote work in 2025.[27]
  • Across U.S. chemical and pharmaceutical manufacturing employers, 5.7% of positions were fully remote in 2024.[28]
  • Among U.S. energy, natural-resources and chemicals workers, 25% preferred mostly remote work in 2025.[27]

Hybrid Work in the chemicals and materials sector (sector benchmark)

  • Across U.S. chemical and pharmaceutical manufacturing employers, 44.5% of positions were fully hybrid in 2024.[28]
  • Across U.S. remote-capable employees, 61% preferred a hybrid work arrangement in November 2025.[26]
  • Across U.S. remote-capable employees, 54% worked in a hybrid arrangement in August 2026.[26]
  • U.S. hybrid employees spent an average of 46% of their workweek on-site in 2026.[26]
  • Across U.S. hybrid employees, 48% said their team had not discussed a formal or informal collaboration plan in 2026.[26]

Upskilling in the clean room pharmaceutical industry

  • 6,640 biopharmaceutical manufacturing employees in Ireland were projected to need training, reskilling or upskilling in 2024.[29]
  • 65% of pharmaceutical manufacturing organizations reported actively engaging in employee upskilling and reskilling in 2025.[30]
  • 8,439 biopharmaceutical manufacturing employees in Ireland were projected to need training, reskilling or upskilling in 2027.[29]
  • 7,782 biopharmaceutical manufacturing employees in Ireland were projected to need training, reskilling or upskilling in 2026.[29]
  • 36,190 cumulative biopharmaceutical manufacturing employees in Ireland were projected to need training, reskilling or upskilling during 2023–2027.[29]

Employee Engagement in the chemicals and materials sector (sector benchmark)

  • Across best-practice organizations recognized by Gallup, 70% of employees were engaged in 2025.[26]
  • Across employees in the United States and Canada, 31% were engaged at work in 2025.[26]
  • Across employees in the United States, 32% were engaged at work in 2025.[26]
  • Among global managers, 22% were engaged at work in 2025, compared with 19% of non-managers.[26]
  • Across employees worldwide, 20% were engaged at work in 2025.[26]

DEI in the clean room pharmaceutical industry

  • Approximately 74% of Amneal Pharmaceuticals’ U.S. workforce identified as diverse by race or ethnicity in 2024.[31]

08 Statistics

Customer & Sales

Buyer satisfaction differs by construction approach, with average modular cleanroom satisfaction at 9.3 out of 10 in 2024. Sales growth is separated into indirect and direct cleanroom-equipment CAGRs.

Customer experience in the clean room pharmaceutical industry

  • 5.3 out of 10 was the average satisfaction score for stick-built cleanrooms among U.S. pharmaceutical-compounding cleanroom users surveyed in 2024.[32]
  • 9.3 out of 10 was the average satisfaction score for modular cleanrooms among 14 U.S. respondents in a 2024 survey of pharmaceutical-compounding cleanroom users.[32]
  • 97% of hospitals reported satisfaction with compounding aseptic isolators across vendors in a U.S. pharmacy-compounding survey.[33]
  • 98% of hospitals reported satisfaction with laminar-airflow workbenches in a U.S. pharmacy-compounding survey.[33]

Customer acquisition in the clean room pharmaceutical industry

  • 8.1% was the projected 2025–2035 CAGR for indirect cleanroom-equipment sales worldwide.[34]
  • 67.7% of global cleanroom-equipment revenue came from direct sales in 2025, equal to approximately $3.8 billion.[34]
  • 32.3% of global cleanroom-equipment revenue came from indirect sales in 2025, equal to approximately $1.8 billion.[34]
  • 7.2% was the projected 2025–2035 CAGR for direct cleanroom-equipment sales worldwide.[34]

09 Statistics

Marketing & Brand

Brand spend is not measured here, but adoption of influencer marketing is quantified for B2B firms. The cleanroom-technology market value attributable to pharmaceutical end users is given for 2022 and 2024.

Marketing in the clean room pharmaceutical industry

  • 6.9% was the projected 2022–2029 CAGR for the U.S. pharmaceutical cleanroom-technology market.[35]
  • $1.155 billion was the U.S. cleanroom-technology market value attributable to pharmaceutical end users in 2022.[35]
  • 10% of QleanAir’s total net revenue came from cleanrooms in 2024, with the business focused on U.S. hospital pharmacies and drug preparation.[36]
  • $1.286 billion was the U.S. cleanroom-technology market value attributable to pharmaceutical end users in 2024.[35]
  • $1.790 billion was the projected U.S. pharmaceutical cleanroom-technology market value for 2029.[35]

Influencer Marketing in the chemicals and materials sector (sector benchmark)

  • Across B2B companies, 29% of marketers planned to adopt influencer marketing within the following year in a March 2025 Ipsos survey.[37]
  • In U.S. manufacturing, 19% of marketers used influencer marketing among paid channels in the prior 12 months, according to a 2025 industry benchmark.[38]
  • Across B2B companies, 81% of marketers had a dedicated influencer-marketing budget in a September 2024 U.S. survey of firms with at least 100 employees.[39]
  • Across B2B companies, 43% of marketers reported outstanding results from influencer programs in the 2025 B2B Influencer Marketing Report.[40]
  • Across B2B companies, 56% of marketers identified social-media posts as the most effective influencer-program content type in a September 2024 U.S. survey.[39]

10 Statistics

Operations & Execution

Energy and airflow optimization show quantified savings in cGMP rooms, including $516,000 annually from reducing airflow in 172 Roche/Genentech cleanrooms. The section also records performance and lot-acceptance metrics.

Process optimization in the clean room pharmaceutical industry

  • 118,997 cubic feet per minute of airflow was identified as reducible across Roche/Genentech’s 172 cGMP cleanrooms in the United States, in 2023.[4]
  • 297,000 therms of natural gas and 2.439 million kWh of electricity were estimated as annual reduction opportunities from cleanroom airflow optimization at a Roche/Genentech site, based on 2018 utility rates.[4]
  • More than 2,400 metric tons of annual carbon-dioxide reduction were estimated from cleanroom airflow optimization at a Roche/Genentech site, based on 2018 utility and energy assumptions.[4]
  • 10 air changes per hour were sufficient to maintain required air quality in a pharmaceutical ISO 8/Class C cleanroom, compared with the commonly used 20 air changes per hour, in 2022 Germany.[41]
  • 41% of electricity consumption at Genentech California sites was attributed to process and equipment, while ventilation accounted for 35%, in 2023.[42]

Operational efficiency in the clean room pharmaceutical industry

  • $312,000 in annual energy-cost savings was estimated for 70 Roche/Genentech BZ 3.1 cGMP rooms after airflow reduction, in the United States, in 2023.[4]
  • $516,000 in annual energy-cost savings was estimated from reducing airflow in 172 Roche/Genentech cGMP cleanrooms in the United States, in 2023.[4]
  • $22,000 in annual energy-cost savings was estimated for 13 Roche/Genentech BZ 2 cGMP rooms after airflow reduction, in the United States, in 2023.[4]
  • $169,000 in annual energy-cost savings was estimated for 33 Roche/Genentech BZ 4.1 cGMP rooms after airflow reduction, in the United States, in 2023.[4]

Quality management in the clean room pharmaceutical industry

  • 33% was the human-error deviation rate for one site category in the ISPE Quality Metrics Pilot Program Wave 2, in 2016.[42]
  • 89% was the median right-first-time rate reported for one site category in the ISPE Quality Metrics Pilot Program Wave 2, in 2016.[42]
  • 7% was the employee-turnover rate for one site category in the ISPE Quality Metrics Pilot Program Wave 2, in 2016.[42]
  • 99% was the reported lot-acceptance rate per finally dispositioned lots for three site categories in the ISPE Quality Metrics Pilot Program Wave 2, in 2016.[42]
  • 59% was the planned-maintenance rate for one site category in the ISPE Quality Metrics Pilot Program Wave 2, in 2016.[42]

Supply chain in the clean room pharmaceutical industry

  • 3.1% of cost of goods sold was the median pharmaceutical warehousing cost in a McKinsey industry analysis published in 2016.[43]
  • 2.0% of cost of goods sold was the median pharmaceutical write-off cost in a McKinsey industry analysis published in 2016.[43]
  • $5 billion to $10 billion was the estimated industry-wide pharmaceutical earnings-before-interest-and-tax potential from supply-chain collaboration, in 2016.[43]
  • 2.1% of cost of goods sold was the median pharmaceutical supply-chain staffing cost in a McKinsey industry analysis published in 2016.[43]
  • 1.5% to 3.5% of cost of goods sold was the estimated improvement potential across major pharmaceutical supply-chain cost areas from collaboration, in 2016.[43]

Outsourcing / Offshoring in the chemicals and materials sector (sector benchmark)

  • Across North American specialty chemicals, 100% of customer respondents allocated only 0–25% of company capital expenditure to reshoring projects in 2025.[44]
  • Across 22 EU countries and Norway, 72.8% of enterprises engaged in international sourcing moved business functions to other EU countries during 2021–2023.[45]
  • Across North American specialty chemicals, 43% of customer respondents actively drove onshoring projects with suppliers and achieved some success in 2025.[44]
  • Across 22 EU countries and Norway, 34.1% of enterprises engaged in international sourcing cited labour-cost reduction as a motivation during 2021–2023.[45]
  • Across North American specialty chemicals, 50% of customer respondents were actively pushing onshoring projects in 2025.[44]

11 Statistics

Finance & Pricing

Pricing constraints link to facility build cost and energy economics, including ISO 5 costing about $400–$600 or more per square foot in 2025. HVAC electricity attribution and quantified airflow savings connect operations to spend.

Cost reduction in the clean room pharmaceutical industry

  • $312,000 per year was the estimated energy-cost reduction for Roche/Genentech BZ 3.1 cGMP rooms after airflow reduction, in the United States, in 2023.[4]
  • $169,000 per year was the estimated energy-cost reduction for Roche/Genentech BZ 4.1 cGMP rooms after airflow reduction, in the United States, in 2023.[4]
  • More than $400,000 per year was the estimated energy saving from cleanroom airflow optimization at a Roche/Genentech site, based on 2018 utility rates.[4]
  • $516,000 per year was the estimated energy-cost reduction from Roche/Genentech’s cGMP cleanroom airflow-reduction program in the United States, in 2023.[4]
  • 50% to 75% of total electrical energy use was attributed to HVAC systems in pharmaceutical cleanrooms in an energy-demand study published in 2019.[41]

Profitability in the clean room pharmaceutical industry

  • 25.8% was Hikma Pharmaceuticals’ reported operating margin for injectables in 2025.[46]
  • $649 million was Hikma Pharmaceuticals’ reported injectables gross profit in 2025.[46]
  • 31.0% was Hikma Pharmaceuticals’ core operating margin for injectables in 2025.[46]
  • $1.423 billion was Hikma Pharmaceuticals’ 2025 revenue from injectables manufactured for hospitals across the United States, Europe and MENA.[46]
  • 46.7% was Hikma Pharmaceuticals’ core gross margin for injectables in 2025.[46]

12 Statistics

Product & Service

Market scope spans equipment, consumables and services, while product classification includes ISO 5, modular and standard facilities. A reference cost is provided for high-specification ISO 5 pharmaceutical facilities.

Product development in the clean room pharmaceutical industry

  • Nearly 50% of pharmaceuticals in development were biopharmaceuticals, increasing demand for complex, high-containment cleanroom capacity, globally, 2019.[10]
  • The pharmaceutical industry represented less than 40% of total cleanroom-market revenue, globally, 2019.[10]
  • Pharmaceutical cleanroom revenue was estimated at about $5 billion annually, worldwide, 2019.[10]
  • About 55% of cleanroom-market revenue involved biopharmaceutical facilities, reflecting their greater containment and process complexity, globally, 2019.[10]
  • Approximately 15,000 pharmaceutical cleanrooms were forecast for 2030, worldwide.[10]

Product lifecycle in the clean room pharmaceutical industry

  • Stick-built cleanroom structures typically supported only one product lifecycle, while prefabricated or podular facilities could be refurbished and reused, globally, 2019.[10]
  • Europe generated $620.24 million, representing 28.85% of global modular-cleanroom revenue, in 2025.[47]
  • Latin America generated $97.39 million, representing 4.53% of global modular-cleanroom revenue, in 2025.[47]
  • North America generated $695.36 million, representing 32.34% of global modular-cleanroom revenue, in 2025.[47]
  • Pharmaceutical high-specification ISO 5 cleanrooms cost approximately $400–$600 or more per square foot, including filtration and HVAC, in 2025.[47]

After-sales in the clean room pharmaceutical industry

  • QleanAir’s 2024 cleanroom portfolio revenue comprised 67% cabin solutions, 23% air cleaners and 10% drug-preparation cleanrooms, globally.[36]
  • QleanAir reported several major cleanroom contracts with private and public healthcare providers in the United States in 2024.[36]
  • QleanAir focused its cleanroom business entirely on the United States during 2024.[36]
  • Cleanrooms represented approximately 10% of QleanAir’s total net revenue, in 2024.[36]
  • Offline dealers and distributors were described as providing technical support and after-sales service for cleanroom customers, globally, 2022.[48]

Value proposition in the clean room pharmaceutical industry

  • QleanAir stated that its cleanroom solutions help ensure medicine quality and sustainability while protecting staff and patients, United States, 2024.[36]
  • The U.S. pharmaceutical cleanroom-technology market was forecast to grow at a 6.9% CAGR from 2022 to 2029.[35]
  • The U.S. pharmaceutical cleanroom-technology market was valued at $1,154.7 million in 2022.[35]
  • The U.S. pharmaceutical cleanroom-technology market was projected to reach $1,790.3 million by 2029.[35]
  • North America held 32.34% of global modular-cleanroom revenue, equivalent to $695.36 million, in 2025.[47]

13 Statistics

Sustainability & Ethics

HVAC and utility projects translate into quantified energy and carbon outcomes, including 59% lower absolute Scope 1 and 2 emissions reported by Roche/Genentech from 2004 to 2023. Single-use waste practices show a large usage gap versus return rates.

Sustainability in the clean room pharmaceutical industry

  • Up to 55% energy savings were identified through building modelling for an air-handling-unit solution at a major pharmaceutical manufacturer.[49]
  • $678,000 in annual operating-cost savings resulted from Roche/Genentech’s cleanroom airflow-reduction project at Oceanside.[4]
  • 20% lower cleanroom airflow during unoccupied hours was implemented by KeyPlants while maintaining pharmaceutical cleanroom integrity.[49]
  • 37% lower energy use and 75% lower water use were reported for Sartorius’s LEED Platinum pharma-bio cleanroom manufacturing facility.[50]
  • 23% annual site-energy savings, equal to 4,283 MWh, were identified at a UK vaccine manufacturing facility through 24 energy and water projects.[51]

ESG in the clean room pharmaceutical industry

  • 59% lower absolute Scope 1 and 2 greenhouse-gas emissions were reported by Roche/Genentech from 2004 to 2023 while revenue more than doubled.[4]
  • 1,445 tonnes of annual carbon-dioxide savings were identified at a UK vaccine manufacturing facility through energy and water projects.[51]

Circular economy in the clean room pharmaceutical industry

  • 48.1% of biopharmaceutical survey respondents said single-use devices should be returned to manufacturers, while only 4.9% said their facilities actually used that practice in 2023.[52]
  • 38% of respondents classified all single-use assembly waste at their biopharmaceutical facilities as biological or regulated medical waste in 2024.[4]
  • 40.7% of surveyed biopharmaceutical facilities used incineration as medical waste for single-use materials in 2023.[52]
  • 23% of respondents classified all single-use assembly waste at their biopharmaceutical facilities as nonhazardous waste in 2024.[4]
  • Less than 15% of biopharmaceutical manufacturing respondents used chemical or mechanical recycling for single-use assemblies in 2024.[4]

Carbon footprint in the clean room pharmaceutical industry

  • 1,025 metric tonnes of carbon-dioxide reduction were reported for a pharmaceutical cleanroom humidity-control project at Hanlim Pharmaceutical.[53]
  • 1,445 tonnes of annual CO2 savings were identified at a UK vaccine manufacturing facility through HVAC, boiler, fresh-air and other efficiency projects.[51]

15 Statistics

Globalization & Expansion

International deployment is measured by facility coverage and capacity, including more than 200 cleanroom and biocontainment facilities across six continents by 2023. Modular-production capacity figures are also tracked by region and plant.

Globalization in the clean room pharmaceutical industry

  • More than 200 cleanroom and biocontainment facilities had been deployed across six continents by Germfree by 2023.[23]
  • 38+ countries were covered by Pharma United’s cleanroom customers in 2025.[59]
  • Six continents contained Germfree facilities by 2023, reflecting international deployment of modular pharmaceutical and biocontainment cleanrooms.[23]
  • 10 countries hosted Sanofi vaccine industrial sites at the end of 2023.[60]
  • QleanAir focused its cleanroom business entirely on the United States in 2024 and did not actively market the segment in Europe or Japan.[18]

Supplier management in the clean room pharmaceutical industry

  • 2,400 square metres was the size of the cGMP cleanroom manufacturing facility completed by BES for Terumo Aortic in Glasgow.[15]
  • 600,000 square metres was Pharma United’s annual capacity for metallic and hollow cleanroom sandwich panels in 2025.[59]
  • 130,000 square feet of ISO Class 8 and 9 cleanroom production space will be available at Gerresheimer’s expanded Peachtree City site.[15]
  • Five production plants were under construction or completed at Franz Ziel’s Billerbeck site by 2024 for pharmaceutical cleanroom and aseptic-processing technologies.[15]
  • €6 million was invested by ChemCon in a new GMP-approved ISO 8 cleanroom facility in Freiburg, Germany, in 2024.[19]

Distribution channels in the clean room pharmaceutical industry

  • 17 warehouses, 12 compounding facilities and 10 repackaging facilities supported Fagron’s pharmaceutical-services network in 2024.[16]
  • 50 facilities made up Fagron’s global network in 2024, including 12 compounding facilities and 10 repackaging facilities.[16]
  • 4.3 billion pharmaceutical and consumer-healthcare units were sold by Sanofi in 2023 through its global production and supply network.[60]
  • 4.0 million units of compounded medicine were supplied by Fagron’s operations in 2024.[16]
  • 17 warehouses formed part of Fagron’s 50-facility network in 2024, supporting pharmaceutical compounding and distribution.[16]

Key questions about the clean room pharmaceutical industry

What is the size of the pharmaceutical cleanroom technology market in 2025?
The global pharmaceutical cleanroom technology market was valued at $7.05 billion in 2025.
How fast is the market expected to grow after 2025?
The forecast CAGR for 2026–2033 is 12.30%, with the market projected to reach $19.10 billion by 2033.
Which companies lead the clean room pharmaceutical industry?
Ecolab leads Gitnux's 2026 clean room pharmaceutical ranking with an Overall score of 9.1, with offers cGMP cleaners, disinfectants and contamination-control programs for pharmaceutical plants. G-CON is the highest-ranked prefabricated cleanroom manufacturer at 8.9, with prefabricated POD cleanrooms for pharmaceutical, biotech and advanced-therapy production.
What technology shifts show up most in clinical manufacturing and validation work?
In 2025, 16% implemented AI for real-time validation monitoring in clinical manufacturing and 19% implemented AI-driven digital twins.
How concentrated is the supplier landscape for cleanroom technology used in pharma?
The top-five supplier share was about 38% in 2025, and Illinois Tool Works held more than 5%.
What are the key compliance benchmarks for particle limits in pharma cleanrooms?
FDA guidance cites an ISO 5 limit of 3,520 particles of at least 0.5 micrometres per cubic metre for exposed sterile drug products during aseptic processing.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 11). Clean Room Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/clean-room-pharmaceutical-industry-statistics
MLA
Samuel Norberg. "Clean Room Pharmaceutical Industry Statistics." Gitnux, 11 Nov 2026, https://gitnux.org/clean-room-pharmaceutical-industry-statistics.
Chicago
Samuel Norberg. 2026. "Clean Room Pharmaceutical Industry Statistics." Gitnux. https://gitnux.org/clean-room-pharmaceutical-industry-statistics.

Sources & references

81 sources cited across this report

  1. capgemini.com
  2. a3p.org
  3. arisglobal.com
  4. ispe.org
  5. s3.us-east-1.amazonaws.com
  6. monitor-industrial-ecosystems.ec.europa.eu
  7. ibm.com
  8. cefic.org
  9. oecd.org
  10. pharmamanufacturing.com
  11. manufacturingleadershipcouncil.com
  12. dnb.com
  13. utah.ismworld.org
  14. gpca.org.ae
  15. cleanroomtechnology.com
  16. a.storyblok.com
  17. reinraum.de
  18. attachment.news.eu.nasdaq.com
  19. chemcon.com
  20. pharmtech.com
  21. drugdiscoverytrends.com
  22. pharmaceutical-technology.com
  23. germfree.com
  24. ohiolifesciences.org
  25. merck.com
  26. gallup.com
  27. kpmg.com
  28. naceweb.org
  29. skillsireland.ie
  30. pmmi-fonteva.s3.us-east-1.amazonaws.com
  31. amneal.com
  32. academic.oup.com
  33. pppmag.com
  34. gminsights.com
  35. marketsandmarkets.com
  36. storage.mfn.se
  37. business.linkedin.com
  38. contentmarketinginstitute.com
  39. marketingprofs.com
  40. toprankmarketing.com
  41. doi.org
  42. ispewebassets.org
  43. img.pharmamanufacturing.com
  44. 5418442.fs1.hubspotusercontent-na1.net
  45. ec.europa.eu
  46. hikma.com
  47. pmarketresearch.com
  48. researchandmarkets.com
  49. keyplants.com
  50. pieriarchitects.com
  51. eeco2.com
  52. cphi-online.com
  53. 1-act.com
  54. gerpac.eu
  55. enhesa.com
  56. ismg-cdn.nyc3.cdn.digitaloceanspaces.com
  57. trustarc.com
  58. chemtrec.com
  59. pharma-united.com
  60. sanofi.com
  61. transpireinsight.com
  62. psmarketresearch.com
  63. fortunebusinessinsights.com
  64. fda.gov
  65. gconbio.com
  66. cleanova.com
  67. farmaceuticas.com.br
  68. clean-room.net
  69. ecolab.com
  70. purever.com
  71. itw.com
  72. labconco.com
  73. dupont.com
  74. terrauniversal.com
  75. angstromtechnology.com
  76. colandis.com
  77. bio.org
  78. sartorius.com
  79. qleanair.com
  80. eur-lex.europa.eu
  81. dcatvci.org